Targeted Gene Sequencing for Clonal Haematopoiesis Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively predict and prevent the progression of myeloid malignancies, such as acute myeloid leukemia, due to limited understanding of clonal expansions and the role of specific genetic mutations in somatic cells, particularly in individuals over 50 years old.
Innovation Solution
A method involving genome sequencing to identify missense mutations in genes like DNMT3A, ASXL1, and TET2, along with other mutations, to predict the likelihood of cancer development and initiate personalized treatment or monitoring regimens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If genome sequencing is performed to identify specific genetic mutations in somatic cells, then the ability to predict cancer development improves, but the complexity and cost of the diagnostic process increases
Solution Approach 1:
The patent segments the genome sequencing process into targeted analysis of specific genes (DNMT3A, TET2, ASXL1, PPM1D, BCORL1, SF3B1) rather than whole-genome sequencing. This segmentation maintains high cancer prediction accuracy by focusing on mutations known to be associated with clonal haematopoiesis, while reducing complexity and cost compared to comprehensive genomic analysis.
Solution Approach 2:
The patent applies preliminary action by first identifying the presence of clonal haematopoiesis through detection of specific somatic mutations before full cancer development occurs. This early detection approach allows for prediction of cancer risk based on established mutational signatures, enabling intervention before the full complexity of cancer diagnosis and treatment is required.
2Reliability
If monitoring for clonal haematopoiesis is implemented in individuals over 50, then early cancer detection capability improves, but the resource requirements for screening increase
Solution Approach 1:
The patent applies local quality by tailoring the screening approach to specific age groups (individuals over 50) who have higher risk of clonal haematopoiesis. The monitoring intensity and resource allocation are optimized for this high-risk population, providing early cancer detection capability where it is most needed while avoiding unnecessary screening of lower-risk individuals.
Solution Approach 2:
The patent changes the parameter of screening frequency and depth based on the presence of specific mutations. Individuals with detected somatic mutations in clonal haematopoiesis-associated genes undergo more intensive monitoring, while those without such mutations receive standard care. This parameter-based stratification improves early detection efficiency while optimizing resource utilization.
Data Source
AI summary
The present invention relates to clonal expansion of somatic cells in subjects, and acquired selective advantage of cell clones during the lifetime of a subject. In particular, the invention relates to methods for predicting the development of cancer based on the observation of specific genetic mutations in somatic cell clones, as well as to methods for treating or preventing cancer in a subject, in which clonal expansion of cells comprising specific modifications is observed.